Observed Outcomes Associated With Fluticasone Propionate/Salmeterol Xinafoate or Inhaled Corticosteroids in Asthma Patients

NCT ID: NCT01431924

Last Updated: 2013-02-25

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 7779 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2010-10-31
• Study Completion Date: 2012-01-31

Brief Summary

This is an observational retrospective analysis of linked pharmacy and medical claims data from IMS Health/Pharmetrics database. which is a comprehensive, de-identified United States (US) healthcare claims database that is representative of the non-elderly, insurance-carrying population, The total population is 35.4 million. The average length of follow-up is 2.7 years mean (2.2 years median).

Subjects will be identified in the database that have at least one ICD-9 diagnostic code (493.xx) for asthma and at least 1 asthma treatment within a 12-month period prior to the index use of fluticsasone propionate/salmeterol xinafoate or inhaled corticosteroids. Subjects will be followed in the database until they have the event of interest (asthma-related emergency department visit, hospitalization, or oral corticosteroid use or combination of asthma-related emergency department/hospitalization or asthma-related emergency department/hospitalization/oral corticosteroids) or until they are lost to follow up whichever comes first. Subjects can be censored if they leave the database, have the event of interest, or are dispensed another asthma controller other than the medication of interest. All outcomes will be assessed in the follow-up period. Time-dependent statistical models adjusting for differences in baseline (pre-index) asthma and patient demographics will be used to compare asthma events.

Conditions

Asthma

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: RETROSPECTIVE

Study Groups

Adolescent and adult patients with asthma

Adolescents and Adults age 12-65 with an ICD-9 code for asthma and a prescription for an inhaled corticosteriod or a corticosteriod/salmeterol combination

Higher-dose inhaled corticosteroids

Intervention Type: DRUG

fluticasone propionate 110 or 220 mcg

Low-dose fixed dose fluticasone propionate/salmeterol xinafoate combination

Intervention Type: DRUG

Low dose inhaled corticosteroids/salmeterol xinafoate (100mcg/50mcg or 250 mcg/50mcg)

Interventions

Higher-dose inhaled corticosteroids

fluticasone propionate 110 or 220 mcg

Intervention Type: DRUG

Low-dose fixed dose fluticasone propionate/salmeterol xinafoate combination

Low dose inhaled corticosteroids/salmeterol xinafoate (100mcg/50mcg or 250 mcg/50mcg)

Intervention Type: DRUG

Other Intervention Names

Flovent® is a registered trademark of GlaxoSmithKline; Advair ® is a registered trademark of GlaxoSmithKline

Eligibility Criteria

Inclusion Criteria

• One or more medical claims with a diagnosis (primary or secondary) of asthma (ICD-9-CM 493.XX) during study period;
• One or more outpatient pharmacy claims during the study for one or more of the following "study medications":
• Fluticasone propionate/salmeterol xinafoate 250 mcg/50 mcg or 100mcg/50mcg combinations
• Fluticasone propionate 110 mcg or 220 mcg
• One or more asthma exacerbations (asthma-related hospitalization or emergency department visit, oral corticosteriod prescription drug claim, or a combination of any of the above events) during the 12 months prior to the index date ("pre-index period") or
• Five or more prescriptions for a short-acting beta agonist during the pre-index period.

Exclusion Criteria

• Patients with more than one of the study medications during the 3-month period beginning with the index date;
• One or more prescriptions within three months of index date (pre or post) for an ICS or LABA other than the study medications
• One or more prescriptions within three months of post index date for:
• Any asthma maintenance medication
• Any medical claims during study period with a diagnosis of: Chronic obstructive pulmonary disease (COPD) (ICD-9-CM 491, 492, or 496); or Respiratory tract cancer (ICD-9-CM 160-164, or 231)

• Minimum Eligible Age: 12 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

GlaxoSmithKline

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Other Identifiers

113903

Identifier Type: -

Identifier Source: org_study_id